Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Reconstitution Monitoring and PCV-21 Vaccination in CAR-T Patients
NCT07071909Phase 2Withdrawn
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pneumococcal 21-valent conjugate vaccine in Pneumococcal pneumonia (PP), sponsored by UNC Lineberger Comprehensive Cancer Center. Planned start Jan 2025; status: withdrawn.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT07071909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071909.